Scholarlink

Background <p>Local recurrence after surgical resection is a major clinical challenge in patients with advanced head and neck cancer (HNC). We previously reported using transfer of a flap treated with dendritic cells (DCs) (“immuno-flap”) as a novel cancer immunotherapy in a rat model of HNC. However, several problems, such as the improvement of DC yield and the verification of DC tracking, remained to be solved.</p> Methods <p>The initial DC production protocol was revisited, and the specific mechanism of the antitumor effect associated with functional DCs was investigated.</p> Results <p>The yield and the purity of potent DCs were improved, and an in vivo tracking experiment revealed that, when injected into the skin flap, the DCs migrated to local lymph nodes within 24&#xa0;h. In an in vivo long-term protection model in which DCs were injected into the skin flap weekly for 4&#xa0;weeks, no strong antitumor effect on HNC tumor progression was observed, but a remarkable pathological effect was verified. Moreover, an enzyme-linked immunospot assay demonstrated that more CD8<sup>+</sup> T cells positive for PD-1, CD40LIG, and TNF-α expression and producing interferon <i>γ</i> specific to SCC-158 tumor cells were identified in tumors and spleens from rats treated using immuno-flaps.</p> Conclusions <p>These results indicate that immuno-flap transfer to prevent local recurrence in patients with HNC has potential for clinical application given the improved yield and quality of antitumor DCs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Hiroaki Mori,
  • Yasuto Akiyama,
  • Chie Maeda,
  • Akari Kanematsu,
  • Tadashi Ashizawa,
  • Kazue Yamashita,
  • Haruo Miyata,
  • Akira Iizuka,
  • Tomoatsu Ikeya,
  • Yoshichika Yasunaga,
  • Jun Araki

摘要

Background

Local recurrence after surgical resection is a major clinical challenge in patients with advanced head and neck cancer (HNC). We previously reported using transfer of a flap treated with dendritic cells (DCs) (“immuno-flap”) as a novel cancer immunotherapy in a rat model of HNC. However, several problems, such as the improvement of DC yield and the verification of DC tracking, remained to be solved.

Methods

The initial DC production protocol was revisited, and the specific mechanism of the antitumor effect associated with functional DCs was investigated.

Results

The yield and the purity of potent DCs were improved, and an in vivo tracking experiment revealed that, when injected into the skin flap, the DCs migrated to local lymph nodes within 24 h. In an in vivo long-term protection model in which DCs were injected into the skin flap weekly for 4 weeks, no strong antitumor effect on HNC tumor progression was observed, but a remarkable pathological effect was verified. Moreover, an enzyme-linked immunospot assay demonstrated that more CD8+ T cells positive for PD-1, CD40LIG, and TNF-α expression and producing interferon γ specific to SCC-158 tumor cells were identified in tumors and spleens from rats treated using immuno-flaps.

Conclusions

These results indicate that immuno-flap transfer to prevent local recurrence in patients with HNC has potential for clinical application given the improved yield and quality of antitumor DCs.